Some of those companies are these three innovative biotech stocks. Let’s take a look at them. ImmunoGen (NASDAQ:IMGN) is making waves in cancer treatment with its flagship product, ELAHERE ...

The biotech chose to add a second candidate in April when it inked a $1.8 billion deal to buy ProfoundBio for a rival to AbbVie’s Elahere. It had a third asset thrust into its hands in August ...

The field researcher from Wild Biotech looks out into the distance in the Falkland Islands while the Juvenile King Penguin looks the other way. Wild Biotech is a preclinical stage drug discovery ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

With the rapid increase in the global population, a "protein crisis" is expected in the near future, where the supply of ...

The United States's dominance in biotech innovation is crucial to our national interests and global security. In recent years, China has quickly become a powerhouse, bolstered by its biotech ...

Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise. Bright Minds shares (DRUG ...

Hello! Hope you had a restful and reflective Indigenous Peoples’ Day. Today, we talk about how the autoimmune disease space is hotter than ever, see more gene therapy contraction, and the CEO of ...

The biotechnology industry is one such industry. This by no means implies that "AI" is useless in biotech; rather, the branding of how useful it is often has little to do with its actual utility.

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history.

Fidelity Select Biotechnology Portfolio earns an Above Average Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance ...

Imbruvica revenues were $828 million (down 8.8%), Venclexta sales increased 14.8% to $677 million, and Elahere's net revenues ... Aliada is a biotechnology company advancing therapies using ...